A treatment algorithm for the management of chronic hepatitis B virus infection in the United States

Emmet B. Keeffe, Douglas T. Dieterich, Steve Huy B Han, Ira M. Jacobson, Paul Martin, Eugene R Schiff, Hillel Tobias, Teresa L. Wright

Research output: Contribution to journalArticle

229 Citations (Scopus)

Abstract

Background & Aims: Chronic hepatitis B is an important public health problem worldwide and in the United States. A treatment algorithm for chronic hepatitis B virus (HBV) infection was developed by a panel of US hepatologists based on new developments in the understanding of the virology of HBV, availability of more sensitive molecular diagnostic testing, and advantages and disadvantages of currently approved therapies. Methods: This algorithm is based on available evidence, but where data are lacking, the panel relied on clinical experience and consensus expert opinion. Results: Serum HBV DNA can be detected at levels as low as 100-1000 copies/mL by using molecular assays and should be determined to establish a baseline level before treatment, monitor response to antiviral therapy, and survey for the development of drug resistance. The primary aim of antiviral therapy is durable suppression of serum HBV DNA to the lowest level possible. The threshold level of HBV DNA for determination of candidacy for therapy is ≥105 copies/mL for patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. A lower serum HBV DNA threshold is appropriate for patients with HBeAg-negative chronic hepatitis B and those with decompensated cirrhosis, and the panel recommends thresholds of 104 copies/mL and 103 copies/mL, respectively. Conclusions: Interferon alfa-2b, lamivudine, and adefovir dipivoxil are all approved as initial therapy for chronic hepatitis B and have certain advantages and disadvantages. Issues for consideration include efficacy, safety, incidence of resistance, method of administration, and cost. Studies are under way to explore the safety and efficacy of combination therapy, which may prove to be more effective than monotherapy in suppressing viral replication and may decrease or delay the incidence of drug resistance.

Original languageEnglish
Pages (from-to)87-106
Number of pages20
JournalClinical Gastroenterology and Hepatology
Volume2
Issue number2
DOIs
StatePublished - Feb 1 2004

Fingerprint

Chronic Hepatitis B
Virus Diseases
Hepatitis B virus
Hepatitis B e Antigens
interferon alfa-2b
DNA
Therapeutics
Drug Resistance
Antiviral Agents
Molecular Diagnostic Techniques
Serum
Safety
Virology
Lamivudine
Incidence
Expert Testimony
Fibrosis
Public Health
Costs and Cost Analysis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. / Keeffe, Emmet B.; Dieterich, Douglas T.; Han, Steve Huy B; Jacobson, Ira M.; Martin, Paul; Schiff, Eugene R; Tobias, Hillel; Wright, Teresa L.

In: Clinical Gastroenterology and Hepatology, Vol. 2, No. 2, 01.02.2004, p. 87-106.

Research output: Contribution to journalArticle

Keeffe, Emmet B. ; Dieterich, Douglas T. ; Han, Steve Huy B ; Jacobson, Ira M. ; Martin, Paul ; Schiff, Eugene R ; Tobias, Hillel ; Wright, Teresa L. / A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. In: Clinical Gastroenterology and Hepatology. 2004 ; Vol. 2, No. 2. pp. 87-106.
@article{f11f5e35c4eb41bca689d4a1ee9fc0f9,
title = "A treatment algorithm for the management of chronic hepatitis B virus infection in the United States",
abstract = "Background & Aims: Chronic hepatitis B is an important public health problem worldwide and in the United States. A treatment algorithm for chronic hepatitis B virus (HBV) infection was developed by a panel of US hepatologists based on new developments in the understanding of the virology of HBV, availability of more sensitive molecular diagnostic testing, and advantages and disadvantages of currently approved therapies. Methods: This algorithm is based on available evidence, but where data are lacking, the panel relied on clinical experience and consensus expert opinion. Results: Serum HBV DNA can be detected at levels as low as 100-1000 copies/mL by using molecular assays and should be determined to establish a baseline level before treatment, monitor response to antiviral therapy, and survey for the development of drug resistance. The primary aim of antiviral therapy is durable suppression of serum HBV DNA to the lowest level possible. The threshold level of HBV DNA for determination of candidacy for therapy is ≥105 copies/mL for patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. A lower serum HBV DNA threshold is appropriate for patients with HBeAg-negative chronic hepatitis B and those with decompensated cirrhosis, and the panel recommends thresholds of 104 copies/mL and 103 copies/mL, respectively. Conclusions: Interferon alfa-2b, lamivudine, and adefovir dipivoxil are all approved as initial therapy for chronic hepatitis B and have certain advantages and disadvantages. Issues for consideration include efficacy, safety, incidence of resistance, method of administration, and cost. Studies are under way to explore the safety and efficacy of combination therapy, which may prove to be more effective than monotherapy in suppressing viral replication and may decrease or delay the incidence of drug resistance.",
author = "Keeffe, {Emmet B.} and Dieterich, {Douglas T.} and Han, {Steve Huy B} and Jacobson, {Ira M.} and Paul Martin and Schiff, {Eugene R} and Hillel Tobias and Wright, {Teresa L.}",
year = "2004",
month = "2",
day = "1",
doi = "10.1016/S1542-3565(03)00312-4",
language = "English",
volume = "2",
pages = "87--106",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - A treatment algorithm for the management of chronic hepatitis B virus infection in the United States

AU - Keeffe, Emmet B.

AU - Dieterich, Douglas T.

AU - Han, Steve Huy B

AU - Jacobson, Ira M.

AU - Martin, Paul

AU - Schiff, Eugene R

AU - Tobias, Hillel

AU - Wright, Teresa L.

PY - 2004/2/1

Y1 - 2004/2/1

N2 - Background & Aims: Chronic hepatitis B is an important public health problem worldwide and in the United States. A treatment algorithm for chronic hepatitis B virus (HBV) infection was developed by a panel of US hepatologists based on new developments in the understanding of the virology of HBV, availability of more sensitive molecular diagnostic testing, and advantages and disadvantages of currently approved therapies. Methods: This algorithm is based on available evidence, but where data are lacking, the panel relied on clinical experience and consensus expert opinion. Results: Serum HBV DNA can be detected at levels as low as 100-1000 copies/mL by using molecular assays and should be determined to establish a baseline level before treatment, monitor response to antiviral therapy, and survey for the development of drug resistance. The primary aim of antiviral therapy is durable suppression of serum HBV DNA to the lowest level possible. The threshold level of HBV DNA for determination of candidacy for therapy is ≥105 copies/mL for patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. A lower serum HBV DNA threshold is appropriate for patients with HBeAg-negative chronic hepatitis B and those with decompensated cirrhosis, and the panel recommends thresholds of 104 copies/mL and 103 copies/mL, respectively. Conclusions: Interferon alfa-2b, lamivudine, and adefovir dipivoxil are all approved as initial therapy for chronic hepatitis B and have certain advantages and disadvantages. Issues for consideration include efficacy, safety, incidence of resistance, method of administration, and cost. Studies are under way to explore the safety and efficacy of combination therapy, which may prove to be more effective than monotherapy in suppressing viral replication and may decrease or delay the incidence of drug resistance.

AB - Background & Aims: Chronic hepatitis B is an important public health problem worldwide and in the United States. A treatment algorithm for chronic hepatitis B virus (HBV) infection was developed by a panel of US hepatologists based on new developments in the understanding of the virology of HBV, availability of more sensitive molecular diagnostic testing, and advantages and disadvantages of currently approved therapies. Methods: This algorithm is based on available evidence, but where data are lacking, the panel relied on clinical experience and consensus expert opinion. Results: Serum HBV DNA can be detected at levels as low as 100-1000 copies/mL by using molecular assays and should be determined to establish a baseline level before treatment, monitor response to antiviral therapy, and survey for the development of drug resistance. The primary aim of antiviral therapy is durable suppression of serum HBV DNA to the lowest level possible. The threshold level of HBV DNA for determination of candidacy for therapy is ≥105 copies/mL for patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. A lower serum HBV DNA threshold is appropriate for patients with HBeAg-negative chronic hepatitis B and those with decompensated cirrhosis, and the panel recommends thresholds of 104 copies/mL and 103 copies/mL, respectively. Conclusions: Interferon alfa-2b, lamivudine, and adefovir dipivoxil are all approved as initial therapy for chronic hepatitis B and have certain advantages and disadvantages. Issues for consideration include efficacy, safety, incidence of resistance, method of administration, and cost. Studies are under way to explore the safety and efficacy of combination therapy, which may prove to be more effective than monotherapy in suppressing viral replication and may decrease or delay the incidence of drug resistance.

UR - http://www.scopus.com/inward/record.url?scp=0842304907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842304907&partnerID=8YFLogxK

U2 - 10.1016/S1542-3565(03)00312-4

DO - 10.1016/S1542-3565(03)00312-4

M3 - Article

C2 - 15017613

AN - SCOPUS:0842304907

VL - 2

SP - 87

EP - 106

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 2

ER -